Imatinib (Figure 2) was the first-in-class protein kinase inhibitor approved by the FDA in 2001 and had a revolutionary impact on the treatment of most cases of chronic myeloid leukemia (CML) [12,13]. The gene discussed is WEE1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.